No satisfactory treatment exists for PAD. Patients' own experience of improved quality of life when their symptoms have been improved indicates that they are satisfied.
Patients with all primary antibody deficiencies report symptoms within weeks. Some patients will require investigations in their later life to further delineate the clinical course and underlying immunodeficiency. No specific investigations are warranted to identify PADs.
About 0.27% of United States adults age >60 years report having a primary antibody deficiency. These data suggest primary antibody deficiencies may be significantly more common than previously reported.
Rituximab (Rituxa), an anti-CD20 monoclonal antibody, is a new therapy for more than 30 years, and has been the main treatment for patients with primary IgM neoplasia for more than 20 years. Other options for primary IgG deficiencies include rituximab and adalimumab (Humira); intravenous immunoglobulin (IVIG) (usually for prolonged use); a humanized, anti-CD20 monoclonal antibody, such as ocrelizumab (Ocrevus, by Orthoclone/Tysabri)) in the US and ofatumumab (Arzerra, by Merck & Co.
The number of PADs has increased over the last 10 years, due in part to increased use of antibiotics, and especially due to the increased use of vaccinations. A large proportion of PAD patients are not being treated in this manner. The most common PADs in adults are IgA deficiency with [IgA nephropathy], IgG deficiency, and hypogammaglobulinemia but there is also a increasing incidence of severe infections caused by PAD, which implies that patients with PAD must be observed for secondary infections.
Primary antibody deficiencies are associated with a decreased risk for IgA2-related disease compared to the general population. The mechanism underlying this observation warrants further investigation. IgA2 antibodies in serum may be a biomarker of immune status in a healthy individual and thus a predictor of a more systemic disease state.
In the last 3 years, research to find new-normal for therapeutic needs has shown encouraging results. These new-normal therapies could be useful in diseases like the following: [diabetes], [hematological malignancies], [heart disease], [hepato-biliary disease], [lung disease], [obesity], [respiratory disease], [kidney disease], [neurologic or neuromuscular diseases], [rheumatic diseases], [bone or cartilage disorders], [neuronal or peripheral disease], [sensorial and psychiatric disorders], [trauma or burn injuries].
Newnormal is safe for most people, including pregnant women. Although its safety during pregnancy is undefined, there is no evidence of it causing harm to mothers prior to childbirth.
There are fewer trials involving newhuman therapy than any other therapy. We must strive to encourage newhuman trials with newhuman-therapy to minimize the negative effects of inadequate clinical trials on the future of stem cell research.
Newnorm effectively normalizes innate immune responses in adults with primary antibody deficiencies by suppressing cytokine production and enhancing IgM class switching in the mucosal immune system. This is of significant importance for long-term immunological health and a key step that may help patients with primary antibody deficiencies live longer in the absence of lifelong immunological surveillance.
Newnorm Provein, when used with an oral iron supplement, is very effective in the treatment of anemia in non-intensive use, and can be used as a substitute for a placebo.
There are a few drugs and therapeutic approaches that are currently being developed to treat these diseases which may be combined as a "triple hit" approach because they inhibit different steps in antibody generation. Because the underlying cellular mechanisms involve different cell types, including B cells, T cells and plasma cells, the therapeutic effect of any such combination approaches could be maximized in such patients.